Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2011

BioNanomatrix Closes $23.3M Financing to Set Up West Coast Presence

  • BioNanomatrix has closed a $23.3 million Series B round of equity financing. The company will use the money to establish a presence on the West Coast for its business, focused on nanoscale, single-molecule imaging and analysis platforms.

    “The Series B financing comes at a pivotal time for the company, as we advance toward commercialization of our unique nanoAnalyzer platform for whole genome analysis,” says R. Erik Holmlin, president and CEO of BioNanomatrix.

    Holmlin says that BioNanomatrix has already placed its nanoAnalyzer 1000 systems with early-access users since introducing the system last November at the 2010 annual meeting of the American Society of Human Genetics.

    BioNanomatrix is based in Philadelphia, and the new West Coast presence “will provide additional business opportunities and the ability to recruit from a talent base that has established this industry,” notes Brian K. Halak, Ph.D., a newly named member of the company’s board of directors.

    Dr. Halak is a partner with Domain Associates, which led the equity financing round. Domain was joined by new investor Gund Investment and existing investors Battelle Ventures, Innovation Valley Partners, and KT Venture Group.




Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »